Comparative Pharmacology
Head-to-head clinical analysis: CERETEC versus IODOHIPPURATE SODIUM I 131.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CERETEC versus IODOHIPPURATE SODIUM I 131.
CERETEC vs IODOHIPPURATE SODIUM I 131
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Technetium-99m exametazime (Ceretec) is a lipophilic radiopharmaceutical that crosses the blood-brain barrier and is taken up by brain tissue in proportion to regional cerebral blood flow. Once inside cells, it undergoes intracellular conversion to a hydrophilic form, trapping it in the brain and allowing SPECT imaging.
Iodohippurate sodium I 131 is a radioactive diagnostic agent that is actively transported by the renal tubules, allowing imaging of renal morphology and function. The iodine-131 emits gamma radiation, enabling scintigraphic evaluation of renal blood flow, tubular secretion, and excretion.
555-740 MBq (15-20 mCi) intravenously as a single dose for SPECT imaging.
Adult: 5-30 microcuries (0.185-1.11 MBq) intravenously for renal function studies.
None Documented
None Documented
Terminal: 6 hours (range 4–8 h); clinical: supports twice-daily dosing in nuclear medicine studies.
Terminal elimination half-life is approximately 60 minutes in patients with normal renal function. In renal impairment, half-life may be prolonged up to several hours, correlating with reduced clearance.
Renal: 40% unchanged; biliary/fecal: 60% (as metabolites and parent compound).
Primarily renal; >90% of administered dose excreted unchanged in urine within 24 hours via glomerular filtration and tubular secretion. Fecal excretion <2%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical